Nanomaterials for Cancer Diagnostics and Therapeutics

描述(由申请人提供)：纳米技术的潜在影响得到了很好的认识，医学领域的重大进步有望首先实现。纳米技术有可能成为肿瘤学和癌症研究进步的根本驱动力，为患者带来短期利益，但必须迎接艰巨的挑战。西北大学建议通过建立癌症纳米材料诊断和治疗中心(CCNE)来应对这些挑战。拟议的CCNE由首席研究员查德·A·米尔金领导，代表着NU Robert H.Lurie综合癌症中心(RHLCCC)和NU国际纳米技术研究所(IIN)之间强有力的综合伙伴关系的发展。RHLCCC是NCI指定的、综合性的、以大学为基础的基质癌症中心，开展广泛的多学科基础、临床和人口科学研究，每年的外部资金超过1.16亿美元。NU国际纳米技术研究所(IIN)是一个伞式组织，它联合了NU的所有纳米技术研究和教育计划，并鼓励和支持与阿贡国家实验室纳米材料中心(CNM)的合作。NU IIN的调查人员目前得到了超过1.3亿美元的外部资金的支持。在国立大学在癌症研究和纳米技术--特别是在检测领域--取得重大进展的基础上，并在一所大学的框架内运作，将使该CCNE能够优化所需的密集整合和合作水平，以创建一条加速发展纳米材料和纳米设备以战胜癌症的途径--从概念到临床试验。其他学术合作者包括芝加哥大学、伊利诺伊大学/厄巴纳-香槟大学和韩国延世大学。

DESCRIPTION (provided by applicant): The potential impact of nanotechnology is well recognized, and significant advances in the medical field are expected to be realized first. It is possible that nanotechnology will be the fundamental driver of advances in oncology and cancer research leading to near-term benefits for patients, and yet formidable challenges must be met. Northwestern University proposes to meet these challenges through the establishment of a Nanomaterials for Cancer Diagnostics and Therapeutics Center for Cancer Nanotechnology Excellence (CCNE). To be led by the Principal Investigator, Chad A. Mirkin, the proposed CCNE represents the development of a strong integrated partnership between the NU Robert H. Lurie Comprehensive Cancer Center (RHLCCC), and the NU International Institute for Nanotechnology (IIN). The RHLCCC is an NCI designated, comprehensive, University-based, matrix cancer center conducting a broad range of multidisciplinary basic, clinical, and population science research with over $116 million dollars in annual extramural funding. The NU International Institute for Nanotechnology (IIN) is an umbrella organization which unites all of the nanotechnology research and educational programs at NU, and encourages and supports collaborations with the Center for Nanoscale Materials (CNM) at Argonne National Laboratory. Investigators in the NU IIN currently are supported by more than $130 million in extramural funding. Building upon the significant advances in cancer research and in nanotechnology - particularly in the detection arena - obtained at NU, and operating within the framework of a single university will permit this CCNE to optimize the intensive level of integration and collaboration required to create an accelerated pathway-from conception to clinical trial-for development of nanomaterials and nanodevices to overcome cancer. Other academic collaborators include the University of Chicago, the University of Illinois/Urbana-Champaign, and Yonsei University, South Korea.